International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 129-134
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Retrospective Review of Metastatic or Recurrent Uterine Sarcomas Treated with Ifosfamide and Doxorubicin (IMA)
Sercan AKSOY1, Deniz HIZLI2, Saynur SARICI2, Reyhan ÖCALAN2, M. Faruk KÖSE2, Nilüfer GÜLER1
1Hacettepe University Institute of Oncology, Department of Medical Oncology, ANKARA
2Etlik Maternity and Women's Health Research Hospital, Department of Gynecologic Oncology, ANKARA
Keywords: Metastasis, Recurrent, Uterine sarcoma, Ifosfamide, Doxorubicin, Chemotherapy
The prognosis of metastatic uterine sarcoma is poor with median survival reported between 4 to 26 months. We evaluated the efficacy and toxicity of ifosfamide (I), mesna (M) and doxorubicin (A) (IMA) chemotherapy regimen retrospectively in patients with metastatic or recurrent uterine sarcomas.
Forty-two patients were enrolled in this study. The median age was 53 years (range, 18-72). Thirty-seven patients were assessable for response and survival; forty patients were assessable for toxicity. A total of 162 cycles of chemotherapy were introduced and for each patient and median number of chemotherapy cycles were 4 (range, 1-6). We observed complete response (CR) in 3 patients; partial response (PR) in 14 patients. Objective RR was 46% (95% CI, 30% to 62%). The median progression-free survival time of the responders was 8.0 months (range, 4-35). The median progression-free survival time of all patients was 5.0 months. Febrile neutropenia was encountered in 6 patients. Dose modifications were required in 4 patients due to myelotoxicity. Central nervous system (CNS) toxicity was observed in three patients. IMA regimen has moderate anti-tumor activity (46%) with acceptable toxicity in patients with recurrent or metastatic uterine sarcomas.
Sercan AKSOY1, Deniz HIZLI2, Saynur SARICI2, Reyhan ÖCALAN2, M. Faruk KÖSE2, Nilüfer GÜLER1
1Hacettepe University Institute of Oncology, Department of Medical Oncology, ANKARA
2Etlik Maternity and Women's Health Research Hospital, Department of Gynecologic Oncology, ANKARA
Keywords: Metastasis, Recurrent, Uterine sarcoma, Ifosfamide, Doxorubicin, Chemotherapy
The prognosis of metastatic uterine sarcoma is poor with median survival reported between 4 to 26 months. We evaluated the efficacy and toxicity of ifosfamide (I), mesna (M) and doxorubicin (A) (IMA) chemotherapy regimen retrospectively in patients with metastatic or recurrent uterine sarcomas.
Forty-two patients were enrolled in this study. The median age was 53 years (range, 18-72). Thirty-seven patients were assessable for response and survival; forty patients were assessable for toxicity. A total of 162 cycles of chemotherapy were introduced and for each patient and median number of chemotherapy cycles were 4 (range, 1-6). We observed complete response (CR) in 3 patients; partial response (PR) in 14 patients. Objective RR was 46% (95% CI, 30% to 62%). The median progression-free survival time of the responders was 8.0 months (range, 4-35). The median progression-free survival time of all patients was 5.0 months. Febrile neutropenia was encountered in 6 patients. Dose modifications were required in 4 patients due to myelotoxicity. Central nervous system (CNS) toxicity was observed in three patients. IMA regimen has moderate anti-tumor activity (46%) with acceptable toxicity in patients with recurrent or metastatic uterine sarcomas.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |